mTORC1 implicated in Still’s disease and MAS

Nature Reviews Rheumatology, Published online: 06 January 2023; doi:10.1038/s41584-023-00908-6New evidence from animal models and human studies suggests that mammalian target of rapamycin has a role in the pathophysiology of Still’s disease and macrophage activation syndrome.

Source: Nature Reviews Rheumatology - January 6, 2023 Category: Rheumatology Authors: Sarah Onuora Source Type: research